Valsartan Colon Cancer Lawsuit Filed Over Medication Contamination

valsartan contamination valsartan lawsuit valsartan colon cancer lawsuit

A recent valsartan colon cancer lawsuit indicates that exposure to the defective generic hypertension drugs that were recalled due to chemical impurities caused a man to develop the life-threatening condition.

Walter Hurens filed the complaint this past month in the Southern District of Mississippi. He is naming Acetris, LLC, and Aurobindo Pharma as defendants.

Hurens indicates he received a generic valsartan prescription in February 2017 to treat high blood pressure. He took the pills for about a year before receiving his colon cancer diagnosis in February 2018. He learned months later that the drugs were part of the recent valsartan recalls that first emerged in the summer of 2018 after cancer-causing impurities were discovered.

According to the valsartan colon cancer lawsuit, the manufacturers failed to disclose the drug contained known carcinogens until the FDA intervened and started issuing drug recalls in July 2018. These carcinogens included N-nitrosodimethylamine (NDMA) or N-Nitrosodiethylamine (NDEA).

“The U.S. Health Department set strict limits on the amount of NDMA that is permitted in each category of food, but these limits are dwarfed by the amount of NDMA present in the samples of the valsartan-containing medications,” the complaint notes.

Since the FDA first announced the recalls, the federal agency has received thousands of questions from doctors, nurses, patients, pharmacists and academics regarding the valsartan contamination. Consequently, the agency has assigned a group of pharmacists and nurses to answer consumer recall questions.

The valsartan colon cancer lawsuit joins a quickly growing number of valsartan recall complaints from individuals who developed cancer following exposure to the contaminated drugs.

Additionally, numerous valsartan class action claims are pursuing damages for healthy patients who used the medications. These patients did not develop cancer but are seeking reimbursement for the essentially worthless drugs, as well as money for medical monitoring for cancer they may require for the remainder of their lives due to exposure to cancer-causing agents.